ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 484

Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use

Myriam Guevara1, Bernard NG1 and Nancy Gove2, 1Rheumatology, University of Washington, Seattle, WA, 2Biostatistics, Seattle Children's, Seattle, WA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Hydroxychloroquine, lipids and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing. The increase in mortality in RA is predominantly due to cardiovascular (CV) disease. Literature suggests that important links exist between RA inflammation and atherosclerosis in CV diseases.Dyslipidemia is a well-known risk factor of atherosclerosis. Previous studies have suggested that anti-malarials, chloroquine diphosphate and hydroxychloroquine(HCQ), used in the treatment of autoimmune diseases, have a beneficial effect on the lipid levels. However the studies had small sample sizes.  We have analyzed a Veterans Affair (VA) RA cohort of 2925 patients to characterize the effect of 4 months use of HCQ in lipid levels.

Methods: Data for this cohort was obtained from the department of VA administrative data base. All adult (age>=18 years) individuals with a diagnosis of RA ( ICD 9 code) at 2 or more  outpatient visits from 1999 to 2009 ,were identified.  Only patients with at least one lipid level measured at 120-180 days prior to staring HCQ were included. Lipids levels at pre start date of HCQ and post start date of HCQ (120-180 days) were compared using students t-test and then adjusted for age, sex, race, CRP and statin use with multivariable regression (ANOVA/ANCOVA) for the change in different lipid levels. To give equal weight to covariables we conducted an analysis of marginal means for race in each lipid level. All analyses were performed with STATA 11.

Results:

Demographics 

 

Yes on Statin

No on Statin

All

Gender

Male (N/%)

402 (15.61%)

2174 (84.39%)

2576

Age (mean/SD)

69 (9.6)

64(12.20)

 

Race

White (N/%)

369 (15.50%)

1868 (83.50%)

2237

AA (N/%)

28 (8.26%)

312 (91.74%)

340

Others (N/%)

13 (3.06%)

123 (4.92%)

136

Unknown (N/%)

15 (3.53%)

197 (7.88%)

212

Pre-CRP mg/dl

(mean/SD)

16.13 (13.53)

5.16 (12.14)

 

Post-CRP mg/dl

(mean/SD)

11.22 (37.9)

5.90(17.94)

 

Lipid changes in HCQ users

 

Pre-mean (SE)

Post-mean (SE)

Total Difference

P value

Cholesterol

176.17 (.87)

171.65 (.90)

4.52

0.00

LDL

103.77 (.76)

98.86 (.76)

4.91

0.00

HDL

45.80 (.32)

46.18 (.32)

-0.38

0.06

Non-HDL

130.37 (.85)

125.46 (.86)

4.91

0.00

AI

4.17 (.38)

4.0 (.03)

0.17

0.00

Lipid changes in HCQ users by statin use groups.

 

Yes Statins

Mean (SD)

No Statins

Mean (SD)

Change in Cholesterol

2.32 (37.72)

2.41 (33.18)

Change in LDL

4.76 (30.52)

5.09 (31.78)

Change in HDL

-0.35 (9.78)

– 0.41 (1.09)

Change in non HDL

2.92 (37.069)

5.52 (32.17)

Change in AI

.068 (1.29)

.164 (1.29)

After adjusting for sex, age, race, statin use and post crp values > 10mg/dl using a linear regression, the factor driving the change in the different lipid levels was race (p values for total cholesterol (TC) 0.006,LDL 0.09, non-HDL 0.03, TC/HDL 0.08 and HDL 0.17). When looking at race individually using marginal means analysis the race in the subgroup others was the more influential. 

Conclusion: Our results suggest gender and race play a role in the effects of HCQ on lipid profiles in RA patients.Use of HCQ in males is found to be associated with positive changes in the lipid profiles independent from the use of statins. There is a suggestion that whites and African Americans might be less susceptivle  to HCQ effect on lipid profiles.


Disclosure: M. Guevara, None; B. NG, None; N. Gove, None.

To cite this abstract in AMA style:

Guevara M, NG B, Gove N. Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/race-plays-a-role-in-influencing-the-modest-lipid-lowering-effects-of-hydroxychloroquine-in-patients-with-rheumatoid-arthritis-independent-of-statin-use/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/race-plays-a-role-in-influencing-the-modest-lipid-lowering-effects-of-hydroxychloroquine-in-patients-with-rheumatoid-arthritis-independent-of-statin-use/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology